Sarepta stock falls over doubts of faster approval for lead drug

[riky]

Sarepta stock falls over doubts of faster approval for lead drug

By Zeba Siddiqui (Reuters) - Sarepta Therapeutics Inc said data from ongoing studies of its lead drug could be enough for the company to apply for a U.S. approval, but that the regulator was unsure if it was enough to fast-track the review process, sparking a sell-off in the company's shares. ...

Source: You are not allowed to view links. Register or Login